Which has preferable earnings & valuation, XNCR or OGN?

Organon & Co. has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 6.74 -$91.92M -$2.29 N/A Organon & Co. $6.22B 0.57 $187M $0.93 14.40

Is XNCR or OGN more profitable?

Organon & Co. has a net margin of 3.99% compared to Xencor's net margin of -177.10%. Organon & Co.'s return on equity of 99.95% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% Organon & Co. 3.99% 99.95% 6.22%

Which has preferable valuation and earnings, BEAM or XNCR?

Beam Therapeutics has higher revenue and earnings than Xencor. Beam Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beam Therapeutics $139.74M 21.76 -$79.99M -$0.68 N/A Xencor $125.58M 6.74 -$91.92M -$2.29 N/A

Is BEAM or XNCR more profitable?

Beam Therapeutics has a net margin of -39.66% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Beam Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Beam Therapeutics -39.66% -29.00% -22.61% Xencor -177.10% -28.77% -20.52%

Does the media refer more to BEAM or XNCR?

In the previous week, Beam Therapeutics had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for Xencor. Xencor's average media sentiment score of 0.93 beat Beam Therapeutics' score of 0.81 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XNCR or DNLI?

In the previous week, Xencor and Xencor both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat Xencor's score of 0.93 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, XNCR or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Xencor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 6.74 -$91.92M -$2.29 N/A Telix Pharmaceuticals $803.79M 3.70 -$7.12M N/A N/A

Does the media favor XNCR or TLX?

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Xencor. Xencor's average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.38 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is XNCR or DYN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% Dyne Therapeutics N/A -58.28% -46.77%

Does the media refer more to XNCR or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Xencor. Dyne Therapeutics' average media sentiment score of 1.20 beat Xencor's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$11.42 +0.21 (+1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$11.43 +0.01 (+0.09%)

As of 07:52 PM Eastern

Compare

XNCR vs. OGN, BEAM, DNLI, TLX, and DYN

Should you buy Xencor stock or one of its competitors? MarketBeat compares Xencor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xencor include Organon & Co. (OGN), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Xencor compare to Organon & Co.?

Xencor (NASDAQ:XNCR) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Organon & Co. has a net margin of 3.99% compared to Xencor's net margin of -177.10%. Organon & Co.'s return on equity of 99.95% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Organon & Co.	3.99%	99.95%	6.22%

In the previous week, Xencor had 2 more articles in the media than Organon & Co.. MarketBeat recorded 2 mentions for Xencor and 0 mentions for Organon & Co.. Xencor's average media sentiment score of 0.93 beat Organon & Co.'s score of 0.50 indicating that Xencor is being referred to more favorably in the media.

Company	Overall Sentiment
Xencor	Positive
Organon & Co.	Positive

77.4% of Organon & Co. shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xencor presently has a consensus price target of $24.50, suggesting a potential upside of 114.54%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 14.89%. Given Xencor's stronger consensus rating and higher possible upside, equities analysts plainly believe Xencor is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Xencor has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40

Summary

Organon & Co. beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Xencor compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Beam Therapeutics has a net margin of -39.66% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Xencor	-177.10%	-28.77%	-20.52%

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Xencor. Beam Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.76	-$79.99M	-$0.68	N/A
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A

In the previous week, Beam Therapeutics had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for Xencor. Xencor's average media sentiment score of 0.93 beat Beam Therapeutics' score of 0.81 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 58.49%. Xencor has a consensus price target of $24.50, indicating a potential upside of 114.54%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Beam Therapeutics beats Xencor on 11 of the 17 factors compared between the two stocks.

How does Xencor compare to Denali Therapeutics?

Xencor (NASDAQ:XNCR) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

92.9% of Denali Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, Xencor and Xencor both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat Xencor's score of 0.93 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor currently has a consensus target price of $24.50, suggesting a potential upside of 114.54%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 74.21%. Given Xencor's higher probable upside, research analysts plainly believe Xencor is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Xencor has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A
Denali Therapeutics	$330.53M	9.44	-$512.54M	-$2.88	N/A

Summary

Denali Therapeutics beats Xencor on 10 of the 16 factors compared between the two stocks.

How does Xencor compare to Telix Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Telix Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Telix Pharmaceuticals' return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Xencor. Xencor's average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.38 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has higher revenue and earnings than Xencor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A
Telix Pharmaceuticals	$803.79M	3.70	-$7.12M	N/A	N/A

Xencor presently has a consensus price target of $24.50, suggesting a potential upside of 114.54%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 140.88%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Xencor has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats Xencor on 9 of the 12 factors compared between the two stocks.

How does Xencor compare to Dyne Therapeutics?

Xencor (NASDAQ:XNCR) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Dyne Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Xencor. Dyne Therapeutics' average media sentiment score of 1.20 beat Xencor's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Xencor has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

96.7% of Dyne Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xencor currently has a consensus target price of $24.50, suggesting a potential upside of 114.54%. Dyne Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 94.55%. Given Xencor's higher probable upside, research analysts clearly believe Xencor is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Summary

Dyne Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$831.13M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-4.99	17.69	22.39	24.18
Price / Sales	6.74	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	1.28	3.85	9.84	6.72
Net Income	-$91.92M	$75.85M	$3.57B	$337.19M
7 Day Performance	-2.56%	-1.67%	-1.16%	0.48%
1 Month Performance	-10.01%	22.18%	3.85%	5.07%
1 Year Performance	24.95%	21.83%	27.40%	34.25%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.0118 of 5 stars	$11.42 +1.9%	$24.50 +114.5%	+30.7%	$831.13M	$125.58M	N/A	280	Positive News
OGN Organon & Co.	2.402 of 5 stars	$13.37 +0.2%	$11.40 -14.7%	+45.2%	$3.50B	$6.22B	14.37	10,000
BEAM Beam Therapeutics	2.1129 of 5 stars	$29.98 -9.0%	$46.83 +56.2%	+78.9%	$3.39B	$164.01M	N/A	510
DNLI Denali Therapeutics	3.7209 of 5 stars	$19.37 -7.9%	$34.25 +76.8%	+38.6%	$3.34B	N/A	N/A	430	Positive News
TLX Telix Pharmaceuticals	4.4826 of 5 stars	$9.15 -3.0%	$21.13 +130.9%	-45.5%	$3.20B	$803.79M	N/A	1,184	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. OGN, BEAM, DNLI, TLX, and DYN

How does Xencor compare to Organon & Co.?

Summary

How does Xencor compare to Beam Therapeutics?

Summary

How does Xencor compare to Denali Therapeutics?

Summary

How does Xencor compare to Telix Pharmaceuticals?

Summary

How does Xencor compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. OGN, BEAM, DNLI, TLX, and DYN

How does Xencor compare to Organon & Co.?

Is XNCR or OGN more profitable?

Does the media prefer XNCR or OGN?

Do insiders & institutionals believe in XNCR or OGN?

Do analysts prefer XNCR or OGN?

Which has more volatility and risk, XNCR or OGN?

Which has preferable earnings & valuation, XNCR or OGN?

Summary

How does Xencor compare to Beam Therapeutics?

Is BEAM or XNCR more profitable?

Do insiders and institutionals believe in BEAM or XNCR?

Which has preferable valuation and earnings, BEAM or XNCR?

Does the media refer more to BEAM or XNCR?

Do analysts rate BEAM or XNCR?

Which has more volatility & risk, BEAM or XNCR?

Summary

How does Xencor compare to Denali Therapeutics?

Do insiders & institutionals hold more shares of XNCR or DNLI?

Which has more volatility & risk, XNCR or DNLI?

Is XNCR or DNLI more profitable?

Does the media prefer XNCR or DNLI?

Do analysts recommend XNCR or DNLI?

Which has better valuation & earnings, XNCR or DNLI?

Summary

How does Xencor compare to Telix Pharmaceuticals?

Is XNCR or TLX more profitable?

Does the media favor XNCR or TLX?

Which has preferable earnings and valuation, XNCR or TLX?

Do analysts prefer XNCR or TLX?

Which has more risk and volatility, XNCR or TLX?

Summary

How does Xencor compare to Dyne Therapeutics?

Is XNCR or DYN more profitable?

Does the media refer more to XNCR or DYN?

Which has more risk and volatility, XNCR or DYN?

Which has preferable earnings & valuation, XNCR or DYN?

Do institutionals and insiders hold more shares of XNCR or DYN?

Do analysts prefer XNCR or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools